Aligos Therapeutics, Inc. - Common stock (ALGS)
ALGS moved a median of +0.01% 30 minutes after news, and +0.79% by the close. How ALGS actually reacts to news — the realized, point-in-time move the market made, measured across 259 labeled events over the last three years with zero look-ahead.
ALGS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 247 |
| 30-min | +0.01% | 54% | 256 |
| 60-min | +0.01% | 50% | 259 |
| to close | +0.79% | 57% | 258 |
| Middle 50% of ALGS reactions | -1.93% to +2.44% |
|---|---|
| Median reaction (30-min) | +0.01% |
| Measured reactions | 259 |
Half of all Aligos Therapeutics, Inc. - Common stock news events land between -1.93% and +2.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALGS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 20 | -0.72% | 35% | +1.92% |
| Rating reiterations | 16 | -1.14% | 44% | -2.17% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ALGS ranks against every other measured name →
That’s how ALGS usually reacts — get an email when it moves on news →Email me when ALGS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALGS's baseline. Nothing else.
Recent ALGS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 | Press release | GlobeNewswire | +0.00% | -1.47% | |
| Form 8-K Aligos Therapeutics, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | +0.80% | |
| Aligos Therapeutics to Present at the Cantor Global Healthcare Conference | Press release | GlobeNewswire | -2.28% | +0.98% | |
| Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China | Press release | GlobeNewswire | -3.60% | -2.59% | |
| Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +2.87% | +31.82% | |
| Form 10-Q Aligos Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.87% | +31.82% | |
| Form 8-K Aligos Therapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +2.87% | +31.82% | |
| Form S-8 Aligos Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.82% | +1.64% | |
| Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 | Press release | GlobeNewswire | -1.40% | +0.47% | |
| Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection | Press release | GlobeNewswire | -2.14% | -2.75% | |
| Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection | Press release | GlobeNewswire | -2.66% | +3.05% | |
| Form 8-K Aligos Therapeutics, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.81% | |
| Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 | Press release | GlobeNewswire | -0.61% | -2.44% | |
| Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 | Press release | GlobeNewswire | +1.55% | +3.09% | |
| Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results | Press release | GlobeNewswire | -2.46% | +5.40% | |
| Form 10-Q Aligos Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.46% | +5.40% | |
| Form 8-K Aligos Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -2.46% | +5.40% | |
| Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 | Press release | GlobeNewswire | -0.58% | +1.33% | |
| Form ARS Aligos Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.83% | -0.17% | |
| Form DEF 14A Aligos Therapeutics, For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | +3.83% | -0.17% | |
| Form DEFA14A Aligos Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +3.83% | -0.17% | |
| Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.64% | +2.56% | |
| Form 8-K Aligos Therapeutics, For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | -1.68% | -0.61% | |
| Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection | Press release | GlobeNewswire | -4.64% | -5.20% | |
| Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation | Press release | GlobeNewswire | +4.78% | -1.59% | |
| Form 8-K Aligos Therapeutics, For: Apr 14 | SEC filing · Form 8-K | SEC EDGAR | +4.78% | -1.59% | |
| Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.00% | -2.06% | |
| Form 10-K Aligos Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -2.06% | |
| Form 8-K Aligos Therapeutics, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.06% | |
| Form S-8 Aligos Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.06% | |
| Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 | Press release | GlobeNewswire | — | +6.84% | |
| Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) | Press release | GlobeNewswire | +0.00% | +1.31% | |
| Form 8-K Aligos Therapeutics, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -7.55% | |
| Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | — | +0.25% | |
| Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates | Press release | GlobeNewswire | +0.37% | -1.24% | |
| Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer | Press release | GlobeNewswire | +0.12% | +7.57% | |
| Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.09% | +14.51% | |
| Aligos Therapeutics Presents Positive Data at HEP-DART 2025 | Press release | GlobeNewswire | +0.27% | +1.86% | |
| Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +5.10% | +13.27% | |
| Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 | Press release | GlobeNewswire | +1.25% | -4.51% | |
| Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -8.27% | +3.20% | |
| Form 10-Q Aligos Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -8.27% | +3.20% | |
| Form 8-K Aligos Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -8.27% | +3.20% | |
| Aligos Therapeutics to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -2.30% | |
| Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 | Press release | GlobeNewswire | -1.40% | -4.65% | |
| Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.85% | -5.13% | |
| Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 | Press release | GlobeNewswire | +0.00% | +1.25% | |
| Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference | Press release | GlobeNewswire | +0.00% | +5.23% | |
| Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 | Press release | GlobeNewswire | -0.96% | -5.38% | |
| Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting | Press release | GlobeNewswire | +0.65% | +0.37% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALGS section they belong to.
Where else ALGS is measured.
ALGS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aligos Therapeutics, Inc. - Common stock's median reaction calculated?
Every labeled ALGS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 259 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of ALGS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALGS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.